"China and Asia are already the global leaders of Antibody-drug conjugates"

Chime Biologics, based in Asia, has positioned itself as a global leader in the Contract Development and Manufacturing Organisation (CDMO) sector.

- Ayesha Siddiqui

Known for its innovation, the company introduced the world's first modular biopharmaceutical plant, KUBio, to support the entire biologics development process—from cell line creation to commercial manufacturing. Leveraging advanced technology from its Shanghai Innovation Center and a proven track record in IND-enabling through BLA filing at its Wuhan facility, Chime Biologics offers a comprehensive, one-stop solution for CMC (chemistry, manufacturing, and controls) services worldwide. In an interaction with BioSpectrum, Dr Jimmy Wei, President of Chime Biologics, shared insights into the company's rapid growth, trends in the CDMO industry, the rising prominence of Antibody-drug conjugates (ADCs) and Asia's growing role in global biomanufacturing. Edited excerpts;

Dr Jimmy Wei, President, Chime Biologics

Chime Biologics has a vision to make biologics more accessible and affordable. How does this vision drive your day-to-day operations and long-term strategies?

We are committed to being a global CDMO with industry-leading capabilities and efficiency, focusing on operational excellence and cost reduction. This vision drives our one-center strategy, which centralizes all operations at our single operational center unlike multiple facilities favoured by some competitors. With this strategy, we ensure streamlined processes and minimal duplication, significantly reducing the costs of manufacturing while maintaining high quality. For example, as we expand our manufacturing capacity from 10,000L to 30,000L by 2025—a threefold increase—we are only increasing our workforce by 50 percent.

What are the key factors behind your rapid growth and success in the CDMO sector?